Literature DB >> 2024503

trans-activation of the HIV-1 LTR by the HIV-1 Tat and HTLV-I Tax proteins is mediated by different cis-acting sequences.

K Zimmermann1, M Dobrovnik, C Ballaun, D Bevec, J Hauber, E Böhnlein.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) gene expression is regulated by viral and cellular factors interacting with cis-elements located in the retroviral long terminal repeat (LTR). In this report we analyzed HIV-1 LTR-specific regulatory sequences responsive to the HIV-1 Tat and HTLV-I Tax trans-activator proteins. Our results indicate that the Sp1 binding sites in the HIV-1 LTR are crucially involved in Tat-mediated gene expression in human Jurkat T-cells whereas they are dispensable for HTLV-I Tax-induced activation. In contrast, the NF-kB binding sites within the HIV-1 LTR are essential for Tax-mediated transcription but had only marginal effect on Tat-induced reporter gene expression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2024503     DOI: 10.1016/0042-6822(91)90633-m

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  Inhibition of bovine endothelial cell activation in vitro by regulated expression of a transdominant inhibitor of NF-kappa B.

Authors:  J Anrather; V Csizmadia; C Brostjan; M P Soares; F H Bach; H Winkler
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

2.  Central nervous system-derived cells express a kappa B-binding activity that enhances human immunodeficiency virus type 1 transcription in vitro and facilitates TAR-independent transactivation by Tat.

Authors:  J P Taylor; R J Pomerantz; G V Raj; F Kashanchi; J N Brady; S Amini; K Khalili
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

3.  Elucidating the Basis for Permissivity of the MT-4 T-Cell Line to Replication of an HIV-1 Mutant Lacking the gp41 Cytoplasmic Tail.

Authors:  Melissa V Fernandez; Huxley K Hoffman; Nairi Pezeshkian; Philip R Tedbury; Schuyler B van Engelenburg; Eric O Freed
Journal:  J Virol       Date:  2020-11-09       Impact factor: 5.103

4.  Identification and characterization of a human herpesvirus 6 gene segment capable of transactivating the human immunodeficiency virus type 1 long terminal repeat in an Sp1 binding site-dependent manner.

Authors:  J Wang; C Jones; M Norcross; E Bohnlein; A Razzaque
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

5.  In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor.

Authors:  K T Jeang; R Chun; N H Lin; A Gatignol; C G Glabe; H Fan
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

6.  Antioxidants selectively suppress activation of NF-kappa B by human T-cell leukemia virus type I Tax protein.

Authors:  R Schreck; R Grassmann; B Fleckenstein; P A Baeuerle
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

7.  Mutational analysis of human T-cell leukemia virus type I Tax: regions necessary for function determined with 47 mutant proteins.

Authors:  O J Semmes; K T Jeang
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

8.  Activation of a heterologous promoter by human immunodeficiency virus type 1 Tat requires Sp1 and is distinct from the mode of activation by acidic transcriptional activators.

Authors:  J Kamine; T Subramanian; G Chinnadurai
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

9.  Adeno-associated virus type 2 rep gene-mediated inhibition of basal gene expression of human immunodeficiency virus type 1 involves its negative regulatory functions.

Authors:  I Oelze; K Rittner; G Sczakiel
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

10.  Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual.

Authors:  A K Iversen; E G Shpaer; A G Rodrigo; M S Hirsch; B D Walker; H W Sheppard; T C Merigan; J I Mullins
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.